Literature DB >> 12150824

A p34(cdc2) survival checkpoint in cancer.

Daniel S O'Connor1, Nathan R Wall, Andrew C G Porter, Dario C Altieri.   

Abstract

A checkpoint surveying the entry into mitosis responds to defects in spindle microtubule assembly/stability. This has been used to trigger apoptosis in cancer cells, but how the spindle checkpoint couples to the cell survival machinery has remained elusive. Here, we report that microtubule stabilization engenders a survival pathway that depends on elevated activity of p34(cdc2) kinase and increased expression of the apoptosis inhibitor and mitotic regulator, survivin. Pharmacologic, genetic, or molecular ablation of p34(cdc2) kinase after microtubule stabilization resulted in massive apoptosis independent of p53, suppression of tumor growth, and indefinite survival without toxicity in mice. By ablating this survival checkpoint, inhibitors of p34(cdc2) kinase could safely improve the efficacy of microtubule-stabilizing agents used to treat common cancers.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12150824     DOI: 10.1016/s1535-6108(02)00084-3

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  84 in total

1.  Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer.

Authors:  Pablo E Vivas-Mejia; Cristian Rodriguez-Aguayo; Hee-Dong Han; Mian M K Shahzad; Fatma Valiyeva; Mineko Shibayama; Arturo Chavez-Reyes; Anil K Sood; Gabriel Lopez-Berestein
Journal:  Clin Cancer Res       Date:  2011-04-21       Impact factor: 12.531

2.  Stalling in mitosis and releasing the apoptotic brake.

Authors:  Manabu Kurokawa; Sally Kornbluth
Journal:  EMBO J       Date:  2010-07-21       Impact factor: 11.598

3.  Survivin is not induced by novel taxanes.

Authors:  Nima Sharifi; Jun Qi; Susan Bane; Shubhada Sharma; Rui Li; Robert Robey; William D Figg; William L Farrar; David G I Kingston
Journal:  Mol Pharm       Date:  2010-10-07       Impact factor: 4.939

4.  Survivin and escaping in therapy-induced cellular senescence.

Authors:  Qin Wang; Peter C Wu; Rachel S Roberson; Belinda V Luk; Iana Ivanova; Elizabeth Chu; Daniel Y Wu
Journal:  Int J Cancer       Date:  2010-05-25       Impact factor: 7.396

5.  Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence-selective DNA binding antitumor agent, hedamycin: evidence of survivin down-regulation associated with drug sensitivity.

Authors:  Jianguo Wu; Xiang Ling; Dalin Pan; Pasha Apontes; Lei Song; Ping Liang; Dario C Altieri; Terry Beerman; Fengzhi Li
Journal:  J Biol Chem       Date:  2005-01-05       Impact factor: 5.157

Review 6.  Role of the Survivin gene in pathophysiology.

Authors:  Fengzhi Li; Michael G Brattain
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

7.  Activation of Cdc2 contributes to apoptosis in HPV E6 expressing human keratinocytes in response to therapeutic agents.

Authors:  Zhi-Guo Liu; Li-Na Zhao; Ying-Wang Liu; Ting-Ting Li; Dai-Ming Fan; Jason J Chen
Journal:  J Mol Biol       Date:  2007-09-18       Impact factor: 5.469

8.  Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter.

Authors:  Jae Yeon Chun; Yan Hu; Elaine Pinder; Jianguo Wu; Fengzhi Li; Allen C Gao
Journal:  Mol Cancer Ther       Date:  2007-09       Impact factor: 6.261

9.  Polymorphisms in the survivin promoter are associated with age of onset of ovarian cancer.

Authors:  Chan H Han; Qingyi Wei; Karen K Lu; Zhensheng Liu; Gordon B Mills; Li-E Wang
Journal:  Int J Clin Exp Med       Date:  2009-10-31

10.  Tumor priming enhances siRNA delivery and transfection in intraperitoneal tumors.

Authors:  Jie Wang; Ze Lu; Bertrand Z Yeung; M Guillaume Wientjes; David J Cole; Jessie L-S Au
Journal:  J Control Release       Date:  2014-01-23       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.